Respiratory infections multiplex, nucleic acid detection (including SARS-CoV-2)
Scheme information
Service
EQAS
Scheme
Respiratory infections multiplex, nucleic acid detection
Service provider
Labquality
Accreditation
Not accredited
Status
New scheme in 2018
Target
Laboratories
Coverage
Analytical phase
Rounds
4
Distributions
Europe, the Middle East and Asia
Coordinator
Jaana Paakkanen
Expert
Matti Waris
Products
5300 / Respiratory infections multiplex, nucleic acid detection
Samples: 4 simulated samples, ≥ 0.5mL each
Type: Physical
Examinations: Direct multiplex nucleic acid detection. Pathogens included are Adenovirus, B. parapertussis, B. pertussis, C. pneumoniae, Coronavirus (OC43, 229E, NL63, HKU1), Enterovirus, Influenzavirus A/B, Metapneumovirus, M. pneumoniae, Parainfluenzavirus 1-4 , Rhinovirus, RSV A/B, SARS-CoV-2, S. pneumoniae
Additional information: Pathogens are covered during annual scheme: participation to all rounds required